XClinical to Present and Exhibit at Upcoming CDISC Interchange in Tokyo
XClinical jointly exhibits with its Japanese CRO partner Asklep at the CDISC Japan Interchange. XClinical has been selected for an ODM training course and for a presentation in the area “Vendor Applications and Tools.”
Munich, Germany-May 26, 2008-XClinical (www.xclinical.com), a European vendor of innovative software products for eClinical trials and known for its innovative and user-friendly CDISC ODM certified EDC software suite MARVIN, today announced its comprehensive participation at the CDISC Interchange in Tokyo, Japan.
The exhibition will take place jointly with Asklep (www.asklep.co.jp), the company’s Japanese customer: “Asklep is the first Japanese CRO to join CDISC, and having a CDISC ODM certified partner like XClinical certainly speeds up our goal for having a global standard EDC solution for our clients here in Japan” said Toshio Yoshii, PhD, director of clinical information division at Asklep.
XClinical executives will be involved in both CDISC presentations and training sessions. Dr. Claus Lindenau, XClinical’s head of business development, will present a lecture entitled "End To End Processing-A presentation of CDISC certified tools and their benefits in clinical research." The presentation will emphasize how the process from study design via data capture to submission and archival can profit from using a combination of CDISC based software solutions.
Dr. Philippe Verplancke, XClinical’s chief executive officer, will lead the ODM training course on Tuesday, June 3. The training provides an in-depth understanding of the CDISC standards, ODM, and define.xml and how the underlying XML technology can support the complete clinical data management process from CRF design to submission.
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
March 6th 2025Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a statistically significant and high level of pain reduction compared to placebo.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Xolair Outperforms Oral Immunotherapy in Landmark Phase III OUtMATCH Food Allergy Trial
March 3rd 2025Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food allergies in the Phase III OUtMATCH trial, suggesting the potential to facilitate the introduction of allergenic foods into patients' diets after treatment.
